11 September 2019 - Public comment period now open until 8 October 2019; Requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review (ICER) today released a Draft Evidence Report assessing the comparative clinical effectiveness and value of oral semaglutide (Novo Nordisk) and other treatments for Type 2 diabetes mellitus.
This draft report will be open to public comment until 5pm ET on 8 October 2019. Based on stakeholder feedback, ICER may revise key assumptions and findings for its Evidence Report, which will be published on 31 October 2019. The Evidence Report will be subject to deliberation during a public meeting of the New England Comparative Effectiveness Public Advisory Council (NE CEPAC), one of ICER’s three independent evidence appraisal committees, on 14 November 2019.